Beyond Air Inc (XAIR)
0.2319
-0.01
(-4.01%)
USD |
NASDAQ |
Apr 07, 16:00
0.2319
0.00 (0.00%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 20.47M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -85.18% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 4.182 |
| Price to Book Value | 1.160 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.0034 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 98.45% |
Profile
Edit
| Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections. |
| URL | https://www.beyondair.net |
| Investor Relations URL | N/A |
| HQ State/Province | New York |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Next Earnings Release | Jun. 24, 2025 (est.) |
| Last Earnings Release | Feb. 10, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
Edit
| Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections. |
| URL | https://www.beyondair.net |
| Investor Relations URL | N/A |
| HQ State/Province | New York |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Next Earnings Release | Jun. 24, 2025 (est.) |
| Last Earnings Release | Feb. 10, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |